Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate therapy, and the time from diagnosis-to-treatment interval can be highly variable with no unive...

Descripción completa

Detalles Bibliográficos
Autores principales: Epperla, Narendranath, Welkie, Rina Li, Torka, Pallawi, Shouse, Geoffrey, Karmali, Reem, Shea, Lauren, Anampa-Guzmán, Andrea, Oh, Timothy S., Reaves, Heather, Tavakkoli, Montreh, Lindsey, Kathryn, Greenwell, Irl Brian, Hansinger, Emily, Thomas, Colin, Chowdhury, Sayan Mullick, Annunzio, Kaitlin, Christian, Beth, Barta, Stefan K., Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L., Herrera, Alex F., Grover, Natalie S., Olszewski, Adam J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165748/
https://www.ncbi.nlm.nih.gov/pubmed/37158890
http://dx.doi.org/10.1186/s13045-023-01448-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165748/
https://www.ncbi.nlm.nih.gov/pubmed/37158890
http://dx.doi.org/10.1186/s13045-023-01448-y

Ejemplares similares